Cargando…
The mTOR Inhibitor Rapamycin Synergizes with a Fatty Acid Synthase Inhibitor to Induce Cytotoxicity in ER/HER2-Positive Breast Cancer Cells
Patients with ER/HER2-positive breast cancer have a poor prognosis and are less responsive to selective estrogen receptor modulators; this is presumably due to the crosstalk between ER and HER2. Fatty acid synthase (FASN) is essential for the survival and maintenance of the malignant phenotype of br...
Autores principales: | Yan, Chen, Wei, Huang, Minjuan, Zheng, Yan, Xue, Jingyue, Yang, Wenchao, Liu, Sheng, Han |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035285/ https://www.ncbi.nlm.nih.gov/pubmed/24866893 http://dx.doi.org/10.1371/journal.pone.0097697 |
Ejemplares similares
-
Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
por: Shi, Pei-Jie, et al.
Publicado: (2016) -
Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor
por: Artoni, Filippo, et al.
Publicado: (2023) -
Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines
por: Lin, Hugo You-Hsien, et al.
Publicado: (2014) -
Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy
por: Zhao, Wei, et al.
Publicado: (2023) -
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
por: García-Martínez, Juan M., et al.
Publicado: (2009)